pl-88, page-10

SS, Thanks for the detailed reply.

I don't know whether I can help you out much with my thoughts because I am more of a sponge than a source of knowledge. However, I have a few previous posts from which you may glean a little historical and background information.

I regard the current SP as very precarious as it has built up on quite low volume and is quite illiquid. I guess its future fluctuations may depend a lot on who has been buying and why. A patient accumulator with a specific agenda or interested spectators. Probably a combination of both. It may stabilise at its present level or shoot in either direction quite suddenly.

As an investment I think the answer lies in the science and the probability of success or failure of the PATRON trial. If successful I imagine the SP will be well north of the current $1 and will only get better after that. Medigen is an established SE Asian company at the epi -centre of the drugs usefulness, thus distribution and marketing should not be a problem. It has also been granted orphan status in both the US and Europe I believe.

Medigen picked up the ball after Progen's surprise exit from the original Phase III trial, so they must have a fair degree of confidence in it. Also, Progen had little difficulty in raising the capital for its trial and there was quite a bit of hype surrounding the drug.[PI-88 failed in a Phase II combination melanoma clinical study begun in 2005 and reported 2012 (long time!) - you may be interested in digging that up]

What you have posted does not exactly fill me with confidence but I am going to sit tight for a while and monitor what eventuates. They are my thoughts for what they are worth.

[I am a bit loath to do this, but have you ever looked into Alchemia (ACL). Briefly, outwardly promising Ph III results soon, metastatic colorectal cancer, platform technology, SP wise appears still under radar, much good HC info, fresh scientific view would be great. I will know if you are interested if you pop up there]